Activation of PPARα is known to stimulate β-oxidation of fatty acids, while PPARγ and PPARβ/δ are involved in modulating lipid uptake, adipogenesis, and inflammation, which collectively support the therapeutic relevance of a pan-PPAR agonist like Polydatin in NAFLD management71. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.